Corcept Therapeutics Incorporated (CORT) News
Filter CORT News Items
CORT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CORT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CORT News From Around the Web
Below are the latest news stories about CORCEPT THERAPEUTICS INC that investors may wish to consider to help them evaluate CORT as an investment opportunity.
Discover 3 US Growth Stocks With Strong Insider OwnershipAs the U.S. stock market experiences a notable upswing, with the S&P 500 and Nasdaq extending their winning streaks, investors are keenly observing growth opportunities amid this positive momentum. In such an environment, companies with strong insider ownership can be particularly appealing as they often indicate confidence in the company's potential for sustained growth. |
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased GuidanceClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Strategy” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The Fed’s rate cut in September contributed to a shift from large-cap generative AI winners to a broader range of market leadership, particularly in small-cap stocks. However, the strategy […] |
Corcept Submits Application for Another Cushing's Syndrome DrugCORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism. |
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With HypercortisolismREDWOOD CITY, Calif., December 30, 2024--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisoli |
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against the other stocks that will make you rich in 2025. What to Expect from the Stock Market in 2025 Jurrien Timmer, Director […] |
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trialThe study showed cardiometabolic improvements and a high tolerance for the therapy with a treatment period of up to six years. |
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with HypercortisolismREDWOOD CITY, Calif., December 16, 2024--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogenous hypercortisolism (Cushing’s syndrome) at the WCIRDC. The results from this |
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control DiabetesOn Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym in patients with hypercortisolism (Cushing’s syndrome) and difficult-to-control type 2 diabetes. Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated b |
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control DiabetesREDWOOD CITY, Calif., December 12, 2024--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism (Cushing’s sy |
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder StudyThe phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal. |